TY - JOUR
T1 - Oral nutritional support can shorten the duration of parenteral hydration in end-of-life cancer patients
T2 - A randomized controlled trial
AU - Ishiki, Hiroto
AU - Iwase, Satoru
AU - Gyoda, Yasuaki
AU - Kanai, Yoshiaki
AU - Ariyoshi, Keisuke
AU - Miyaji, Tempei
AU - Tahara, Yukiko
AU - Kawaguchi, Takashi
AU - Chinzei, Mieko
AU - Yamaguchi, Takuhiro
N1 - Publisher Copyright:
© 2015 Taylor & Francis Group, LLC.
PY - 2015/1/2
Y1 - 2015/1/2
N2 - Tube feeding or hydration is often considered for end-of-life cancer patients despite the negative effects on quality of life. The efficacy of oral nutritional support in this setting is unknown. We conducted a randomized trial to compare the efficacies of an amino acid jelly, Inner Power® (IP), and a liquid enteral product, Ensure Liquid® (EL), in terminally ill cancer patients. We randomly assigned patients to 3 arms: EL, IP, and EL+IP. The primary endpoint was drip infusion in vein (DIV)-free survival, which was defined as the duration from nutritional support initiation to administration of parenteral hydration. Twenty-seven patients were enrolled in the study, of whom 21 were included in the intention-to-treat analysis. The median age of the subjects was 69 yr. There were significant differences between the arms with regard to the median DIV-free survival (0.5, 6.0, and 4.5 days in the EL, IP, and EL + IP arms, respectively; P = 0.05). The median overall survival was 7, 9, and 8 days in the EL, IP, and EL + IP arms, respectively. IP may shorten the duration of parenteral hydration in terminally ill cancer patients and does not affect their survival.
AB - Tube feeding or hydration is often considered for end-of-life cancer patients despite the negative effects on quality of life. The efficacy of oral nutritional support in this setting is unknown. We conducted a randomized trial to compare the efficacies of an amino acid jelly, Inner Power® (IP), and a liquid enteral product, Ensure Liquid® (EL), in terminally ill cancer patients. We randomly assigned patients to 3 arms: EL, IP, and EL+IP. The primary endpoint was drip infusion in vein (DIV)-free survival, which was defined as the duration from nutritional support initiation to administration of parenteral hydration. Twenty-seven patients were enrolled in the study, of whom 21 were included in the intention-to-treat analysis. The median age of the subjects was 69 yr. There were significant differences between the arms with regard to the median DIV-free survival (0.5, 6.0, and 4.5 days in the EL, IP, and EL + IP arms, respectively; P = 0.05). The median overall survival was 7, 9, and 8 days in the EL, IP, and EL + IP arms, respectively. IP may shorten the duration of parenteral hydration in terminally ill cancer patients and does not affect their survival.
UR - http://www.scopus.com/inward/record.url?scp=84920522611&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920522611&partnerID=8YFLogxK
U2 - 10.1080/01635581.2015.976312
DO - 10.1080/01635581.2015.976312
M3 - Article
C2 - 25437180
AN - SCOPUS:84920522611
VL - 67
SP - 105
EP - 111
JO - Nutrition and Cancer
JF - Nutrition and Cancer
SN - 0163-5581
IS - 1
ER -